ea9f5a96-93d4-4724-bc4b-2813fa8a35ae
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 82
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.350
- KRAS_SIGNALING_DN+0.270
- HEDGEHOG_SIGNALING+0.260
- MYC_TARGETS_V2+0.260
- NOTCH_SIGNALING+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.240
- ESTROGEN_RESPONSE_EARLY+0.210
- MYOGENESIS+0.190
- APICAL_SURFACE+0.170
- ESTROGEN_RESPONSE_LATE+0.170
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- ANDROGEN_RESPONSE-0.430
- TGF_BETA_SIGNALING-0.350
- TNFA_SIGNALING_VIA_NFKB-0.320
- UV_RESPONSE_DN-0.310
- ALLOGRAFT_REJECTION-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- KRAS_SIGNALING_UP-0.260
- APOPTOSIS-0.250
- INFLAMMATORY_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.892 |
| 2 | 0ffd0bed-35a4-4fec-9d56-1d4ae5dcb507 | — | — | 0.879 |
| 3 | 4f521ce8-4aac-4ea5-abbe-732ff9ac5409 | — | — | 0.863 |
| 4 | f17e12f0-54ed-4dc2-ab7e-22a1f90e1405 | — | — | 0.831 |
| 5 | c2e34dda-0852-492e-9cde-3ff606259c12 | — | — | 0.828 |
| 6 | MNG545 | — | — | 0.816 |
| 7 | SRR25043618 | — | — | 0.809 |
| 8 | 3e1c728a-cf38-4ca8-9d87-0bbf098567a6 | — | — | 0.804 |
| 9 | 8683d8f5-bba5-40a1-a460-ad6183d2302b | — | — | 0.801 |
| 10 | MNG559 | — | — | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |